Efficiency of Edaravone in Treatment of Amyotrophic Lateral Sclerosis

Efficacy and Safety of Edaravone in Amyotrophic Lateral Sclerosis - ESEALS

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2019/11/021838

Enrollment

Registered

2019-11-01

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G122- Motor neuron disease

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patients, who are more than 18 years of age and are diagnosed to have possible, probable or definite ALS as per the El Escorial Criteria 2014, will be included.

Exclusion criteria

Exclusion criteria: Patients will be excluded if they have liver or kidney disorder (eGFR < 50ml/min), malignancy, uncontrolled hypertension, or any structural brain or spinal cord lesion

Design outcomes

Primary

Measure	Time frame
(i) To find out the efficacy of Edaravone in all patients of amyotrophic lateral sclerosis in improvement with respect todefined parameters at the end of 6 months. (ii) To find out the efficacy of Edaravone in a subset of serving personnel having ALS, military service being a risk factor for ALS Timepoint: 6 and 12 months	—

Secondary

Measure	Time frame
To study the SFEMG parameter measures in ALS patients and correlate them with their clinical evaluationTimepoint: 6 and 12 months	—

Countries

India

Contacts

Public ContactSalil Gupta

ARMY HOSPITAL RR

chickusalil@yahoo.com8197751281

Outcome results